What Does Plaquenil Treat and How Does It Work?

Plaquenil, the brand name for hydroxychloroquine (HCQ), is an immunomodulatory drug used primarily to treat systemic lupus erythematosus and rheumatoid arthritis, with a secondary role as an antimalarial agent. It works by raising the pH inside certain cell compartments, which disrupts the immune system’s ability to trigger inflammation through specific signaling pathways. Despite its origins as a malaria drug in the mid-twentieth century, the overwhelming majority of Plaquenil prescriptions today are written for autoimmune and inflammatory conditions, and the drug’s reach extends well beyond joint pain and rashes.

Lupus and the Case for Continuous Use

Systemic lupus erythematosus (SLE) is the condition most closely associated with Plaquenil. Virtually every lupus treatment guideline worldwide recommends hydroxychloroquine as background therapy for all patients unless they have a specific contraindication. The drug reduces flares, protects organs, and appears to improve long-term survival. A systematic review and meta-analysis of cohort studies found that HCQ use cut overall mortality risk roughly in half compared with nonuse.¹ That is an unusually strong signal for any chronic medication, and it helps explain why rheumatologists are reluctant to stop HCQ even when a patient’s lupus appears quiet.

Dose matters. A study comparing patients on higher versus lower weight-based doses found that those receiving the higher dose had fewer flares and longer flare-free periods, with the risk of flare dropping in a roughly linear fashion as the dose increased.² That creates a practical tension: higher doses protect better against flares but also raise the long-term risk of eye toxicity, which we will get to shortly.

Rheumatoid Arthritis

In rheumatoid arthritis, hydroxychloroquine is rarely prescribed alone. It is most effective as part of combination therapy, and the classic “triple therapy” of methotrexate, sulfasalazine, and hydroxychloroquine has been a workhorse regimen for decades. A landmark randomized trial found that about three-quarters of patients on all three drugs achieved a meaningful clinical response at two years, compared with roughly half of those on just two of the three.³ An earlier trial had shown a similar pattern, with the three-drug combination outperforming both methotrexate alone and the two-drug pair of sulfasalazine and hydroxychloroquine.⁴

The practical question patients often ask is whether they really need all three drugs. The evidence consistently says the combination is greater than the sum of its parts, and all three drugs were well tolerated together. Some treatment strategies start with all three at once, while others “step up” by adding one drug at a time; a trial comparing these two approaches in early rheumatoid arthritis found that starting everything together tended to produce faster improvement.⁵

Other Autoimmune and Skin Conditions

Plaquenil is widely used for autoimmune skin diseases, particularly cutaneous lupus erythematosus, where it is often a first-line treatment. It also sees use in Sjögren’s syndrome, an autoimmune condition that attacks moisture-producing glands. A study of patients with a specific annular skin rash associated with Sjögren’s found that HCQ improved lesions in every patient treated, with the average skin severity score dropping by about 85% within 12 weeks. Among patients whose rash was limited to the face, the majority achieved complete clearance within just four weeks.⁶ The drug also allowed patients who had been on long-term steroids to lower their steroid dose without relapsing, which is valuable because chronic steroid use carries its own serious side effects.

Hydroxychloroquine is also used for other skin manifestations in autoimmune disease. Case reports and small series have documented benefit in cutaneous purpura tied to Sjögren’s syndrome, adding to the growing list of dermatologic applications.⁷

Malaria and Q Fever

Hydroxychloroquine was originally developed as an antimalarial, derived from chloroquine with modifications intended to reduce toxicity. Both drugs accumulate inside the digestive compartment of the malaria parasite, interfering with its ability to safely break down hemoglobin from red blood cells.⁸ However, widespread resistance has sharply limited the usefulness of both drugs against the deadliest malaria species, Plasmodium falciparum. Resistance is driven primarily by mutations in a protein called PfCRT, which sits on the membrane of the parasite’s digestive vacuole and pumps the drug out before it can do its job.⁹ Additional genes contribute to the resistance picture; one study identified a second transporter whose mutations can either potentiate or reduce chloroquine resistance depending on the specific change.¹⁰ Hydroxychloroquine is still sometimes used for malaria prophylaxis in regions without widespread resistance, but it is no longer a go-to treatment in much of the tropics.

One lesser-known infectious disease application: Q fever, a bacterial infection caused by Coxiella burnetii. Since the 1990s, the combination of hydroxychloroquine and doxycycline has been the standard treatment for persistent focalized Q fever. The rationale is that HCQ alkalinizes the compartment where Coxiella hides inside human cells, making the antibiotic more effective. This combination has reportedly shortened treatment courses substantially, although rigorous trial evidence remains sparse.¹¹

How It Actually Works

Plaquenil is what pharmacologists call a “weak base.” When it enters a cell, it gets drawn into acidic compartments like lysosomes and endosomes, where it accumulates and raises the pH. That single physical property sets off a cascade of downstream effects on the immune system. A review of its immunomodulatory mechanisms identified three broad pathways: inhibiting Toll-like receptor (TLR) signaling, suppressing the presentation of antigens to immune cells, and modulating autophagy, the cellular cleanup process that recycles damaged components.¹²

The TLR pathway is probably the most clinically important. TLRs are sensors inside cells that detect fragments of DNA and RNA. In autoimmune diseases like lupus, the immune system mistakenly treats the body’s own nucleic acids as threats, triggering TLRs and producing inflammatory signals called type I interferons. HCQ interferes with this by preventing the TLRs from maturing properly. One study showed that HCQ specifically blocks the cleavage of TLR7, a sensor for single-stranded RNA, so the receptor accumulates in its inactive full-length form and cannot trigger an immune response to RNA.¹³ HCQ similarly dampens activation through TLR9, which senses DNA. In lupus skin disease, patients with the highest TLR9 levels in their skin lesions tended to respond best to treatment, suggesting that the drug’s clinical benefit tracks with how active this particular pathway is in a given patient.¹⁴

Beyond TLR signaling, HCQ reduces the secretion of inflammatory cytokines and type I interferons through interference with cytosolic nucleic acid sensors.¹⁵ There has also been growing interest in the drug’s effects on the cGAS-STING pathway, another cellular alarm system that detects DNA in the wrong place and triggers interferon production.¹⁶ All of these mechanisms converge on the same basic theme: HCQ turns down the volume on immune pathways that are stuck in overdrive.

Why It Takes Weeks to Work

One of the most common frustrations with Plaquenil is the long wait for it to kick in. Patients are often told to expect four to six months before seeing full benefit, and for some people it takes even longer. The explanation lies in the drug’s unusual pharmacokinetics. Hydroxychloroquine has a massive volume of distribution, meaning it spreads extensively into tissues throughout the body rather than staying in the bloodstream. Pharmacokinetic studies in healthy volunteers found that it takes about 40 days for half of a dose to clear the body, and the drug distributes into an apparent tissue volume thousands of liters larger than the blood volume.¹⁷ The drug’s long persistence in the body is driven by this deep tissue storage, not by slow metabolism.¹⁸

This also means that steady-state levels in the blood take months to reach. It is why clinicians sometimes check HCQ blood levels to guide dosing. Research has identified an effective range of blood concentrations that appears to offer the best balance of efficacy and safety. Patients whose blood levels fell within that optimal range had substantially lower odds of active lupus and fewer flares.¹⁹ Critically, prescribed dose did not always predict blood level, meaning two patients on the same pill count could have very different drug concentrations. Among lupus patients followed over time, those who maintained stable blood levels above a certain threshold experienced no disease flares at all, while those with lower levels relapsed more often.²⁰ This underscores the value of monitoring, particularly in patients who seem to be taking the drug faithfully but are still flaring.

Metabolic and Cardiovascular Side Benefits

Plaquenil does something that very few anti-inflammatory drugs can claim: it appears to improve metabolic health. A systematic review and meta-analysis in rheumatoid arthritis patients found that HCQ users had lower total cholesterol, lower LDL cholesterol, lower triglycerides, and higher HDL cholesterol compared with nonusers. The same analysis found that HCQ use was associated with roughly 40% lower odds of developing diabetes.²¹ Case reports have also documented improved blood sugar control in individual patients after starting HCQ, including one patient with type 1 diabetes whose glycemic management improved when HCQ was added for Sjögren’s syndrome.²²

The drug also appears to reduce the risk of blood clots. In patients with antiphospholipid syndrome, a condition that causes abnormal clotting, a pilot randomized trial found that adding HCQ to standard anticoagulation therapy was associated with a markedly lower rate of new blood clots over roughly two and a half years of follow-up. HCQ also appeared to lower the levels of the problematic antibodies themselves over time.²³ These metabolic and vascular perks are part of why the survival benefit of HCQ in lupus is so large. Lupus patients face accelerated cardiovascular disease, and a drug that simultaneously controls inflammation, improves lipids, reduces diabetes risk, and prevents clots addresses multiple contributors at once.

Plaquenil During Pregnancy

Unlike most immunosuppressive drugs, hydroxychloroquine is generally considered safe to continue during pregnancy. In fact, stopping it appears to carry more risk than continuing it. A study of pregnant women with lupus found that those who discontinued HCQ experienced significantly more disease activity during pregnancy and required higher steroid doses, while rates of miscarriage and birth defects did not differ between women who continued and those who stopped.²⁴ A systematic review and meta-analysis confirmed these benefits, finding that HCQ during pregnancy reduced recurrences, lowered disease activity, promoted full-term delivery, and decreased the risks of gestational hypertension and pre-eclampsia.²⁵

The pre-eclampsia finding is generating particular excitement. A large population-based study from Sweden found that pregnant women with lupus who were exposed to HCQ in early pregnancy had about half the risk of developing pre-eclampsia compared with those who were not on the drug.²⁶ Whether HCQ could prevent pre-eclampsia in women without lupus is a separate question still under investigation, but the lupus data have made it a drug that rheumatologists strongly encourage patients to keep taking through pregnancy rather than reflexively stopping “just in case.”

Eye Screening and Retinal Toxicity

The most talked-about long-term risk of Plaquenil is retinal toxicity, sometimes called “bull’s-eye maculopathy” because of the characteristic pattern of damage seen on imaging. The drug accumulates in the retinal pigment epithelium over years, and in a small fraction of long-term users it causes irreversible vision changes. The risk is low in the first five years at recommended doses, but it climbs with longer use and higher cumulative exposure.

Current screening guidelines recommend keeping the daily dose at or below 5 mg per kilogram of real body weight, with an absolute cap of 400 mg per day for severely obese patients. A baseline eye exam including retinal imaging is advised soon after starting the drug, both to rule out pre-existing conditions and to provide a comparison for future screening.²⁷ Annual screening typically begins after five years of use, or sooner if additional risk factors like kidney disease are present.

Research is expanding understanding of what happens before the classic bull’s-eye pattern develops. Animal and clinical work has shown that chronic HCQ exposure damages the inner retina first, reducing the thickness of inner retinal layers and causing loss of retinal ganglion cells before the outer-retinal changes that produce the recognizable bull’s-eye become visible. The underlying damage involves disruption of the autophagy-lysosome system and altered lipid metabolism within retinal cells.²⁸ This is important because it means retinal damage may be detectable earlier than previously thought if clinicians look for it with the right tests. The practical takeaway for patients is simple: get the screening exams on schedule, report any visual changes, and do not exceed the recommended dose.

Rare but Serious Side Effects

Beyond the eyes, hydroxychloroquine can rarely affect the heart. HCQ cardiotoxicity is an uncommon cause of cardiomyopathy, where the heart muscle becomes weakened or stiffened.²⁹ This tends to emerge after years of use and at higher cumulative doses, and it can be difficult to diagnose because the underlying autoimmune disease can also affect the heart. Common gastrointestinal side effects like nausea and diarrhea are more frequent but usually manageable. The overall safety profile is favorable enough that the drug has been used continuously in some patients for decades.

The COVID-19 Chapter

No discussion of Plaquenil is complete without addressing what happened during the COVID-19 pandemic. Early laboratory studies suggested hydroxychloroquine might block SARS-CoV-2 from entering cells, and the drug’s known effects on TLR signaling and interferon pathways gave theoretical reasons for optimism. What followed was an unprecedented rush to use and study the drug before the evidence was in.

The evidence arrived, and it was consistently negative. A large randomized trial of hospitalized patients found no difference in clinical status at 14 days between HCQ and placebo, and no difference in mortality at 28 days.³⁰ A separate trial in non-hospitalized outpatients with COVID-19 found no reduction in hospitalization rates with HCQ compared with placebo.³¹ When researchers tested HCQ as a preventive measure for healthcare workers exposed to the virus, infection rates were identical in the drug and placebo groups.³² Across treatment, early intervention, and prevention, the answer was the same: HCQ did not work against COVID-19.

The pandemic episode had real consequences for lupus and rheumatoid arthritis patients. Panic-buying and off-label prescribing created supply shortages that left people who genuinely depended on the drug unable to fill their prescriptions. It was an object lesson in why treatments need to be tested before they are promoted.

Emerging Research in Oncology

One area of active investigation is whether Plaquenil’s ability to block autophagy could be useful in cancer treatment. Tumor cells sometimes use autophagy to survive the stress of chemotherapy, essentially recycling their own components to stay alive under assault. By blocking autophagy, HCQ and chloroquine might make tumors more vulnerable to conventional cancer drugs. A systematic review and meta-analysis of clinical trials examining this approach found that adding an autophagy inhibitor to cancer therapy was associated with improved overall survival and progression-free survival compared with therapy without autophagy inhibition.³³ The results are promising but preliminary. Most trials were small, and the optimal tumor types, drug combinations, and dosing regimens are still being worked out. This is not a reason for cancer patients to start taking Plaquenil on their own, but it is an intriguing example of how a 70-year-old antimalarial drug keeps finding new applications in medicine.